InSilico Medicine
Develops an AI platform for drug development to treat cancer and age-related diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
$1.1b (Public information from Aug 2022)
Yuen Long District New Territories (HQ)
Financials
Estimates*
USD | 2021 | 2022 |
---|---|---|
Revenues | 40.2m | 48.8m |
% growth | - | 21 % |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$300k | Seed | ||
$1.2m | Convertible | ||
$10.0m | Early VC | ||
N/A | $4.0m | Series A | |
$6.0m | Series A | ||
* | $37.0m | Series B | |
* | N/A | N/A | Series B |
* | $255m | Series C | |
* | $60.0m Valuation: $1.1b | Series D | |
* | $35.0m Valuation: $1.1b | Series D | |
Total Funding | $409m |
Related Content
Recent News about InSilico Medicine
EditInvestments by InSilico Medicine
EditACQUISITION by Regent Pacific Sep 2020